¿Cuál es el verdadero rol de los ACPAs en la artritis reumatoidea?

Rodrigo García Salinas; Gustavo Citera; Sebastián Juan Magri

doi:10.47196/rar.v28i4.549

Rodrigo García Salinas Hospital Italiano de La Plata, Buenos Aires, Argentina
Gustavo Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Sebastián Juan Magri Hospital Italiano de La Plata, Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v28i4.549

Palabras clave: ACPA, artritis reumatoidea

Resumen

Hasta hace algunos años, se consideraban a los ACPAs como el resultado de un epifenómeno de la respuesta inmune en la AR, su detección se centraba en el diagnóstico y clasificación de los pacientes. Recientemente se ha comenzado a demostrar fehacientemente que los ACPAs cumplen un rol central en la fisiopatología de la AR. En esta revisión, exponemos de forma exhaustiva la relación de estos anticuerpos con los factores genéticos ambientales, su interrelación con la función de células T y su participación en la diferenciación de osteoclastos, puntualizando en su dinámica de concentración, isotipos y modificaciones momentos antes del desarrollo de la AR. También hacemos hincapié en otros procesos de modificación de proteínas que se presentan en la AR, como por ejemplo la carbamilación. Por último, resaltamos las implicancias terapéuticas que podrían tener la seropositividad y la seroconversión de estos anticuerpos.

Biografía del autor/a

Rodrigo García Salinas, Hospital Italiano de La Plata, Buenos Aires, Argentina

Especialización Reumatología

Sebastián Juan Magri, Hospital Italiano de La Plata, Buenos Aires, Argentina

Especialización Reumatología. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Cátedra de Inmunología

Citas

I. Witalison E, Thompson P, Lorne H: Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation Curr Drug Targets. Author manuscript; available in PMC 2016 Jan 1.

II. van Venrooij WJ, Pruijn GJ: Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res. 2000;2(4):249-51.

III. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007 Jun 5;146(11):797-808.

IV. Taylor P, Gartemann J, Hsieh J, Creeden J: A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011;2011:815038.

V. Cerna M, Falco M, Friedman H, et al: Differences in HLA class II alleles of isolated South America Indian populations from Brazil and Argentina. Human Immunol 1993;37:213-20.

VI. Citera G, Padulo LA, Fernández G, Lázaro MA, Rosemffet M, Maldonado Cocco JA: Influence of HLA-DR alleles on rheumatoid arthritis: Susceptibility and severity in Argentine patients. J Rheumatol 2001;28:1486-91.

VII. Dal Pra F, Citera G, Landi M, Waimann C, et al: Frecuencia de antígenos leucocitarios humanos en región DR en pacientes con artritis temprana en Argentina. Evaluación de su utilidad como herramienta complementaria para discriminar pacientes con artritis indiferenciada y artritis reumatoidea. Rev Arg de Reum, 2014.

VIII. Padyukov L, Silva C, Stolt P, Alfredsson L & Klareskog L: A gene–environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085-3092.

IX. Mikuls TR et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int . Immunopharmacol. 20009;9:38-42.

X. M almström V, Catrina AI, Klareskog L: The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017 Jan;17(1):60-75.

XI. Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008;35:1009-14.

XII. van Gaalen FA, van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.

XIII. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al: A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010 Jul;69(7):1333-7. 13bis. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al: A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010 Jul;69(7):1333-7.

XIV. Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014 Jan 16;16(1):R13.

XV. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al: Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009 Aug;60(8):2262-71.

XVI. Girard Bosch MP, Garcia Salinas RN, Martire MV, Arturi P, Magri SJ, et al: Optimizing biologic therapy in rheumatology: frequency and characteristics from argentine referral centre. Int. J. Clin. Rheumatol. 2016;11(6):108-112.

XVII. van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM: Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum. 2008 Jan;58(1):53-60.

XVIII. Cohen MD, Keystone E: Rituximab for Rheumatoid Arthritis. Rheumatol Ther. 2015 Dec;2(2):99-111.

XIX. Zhao X, Okeke NL, Sharpe O, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008;10:R94.

XX. Sabharwal UK, Vaughan JH, Fong S, Bennett PH, Carson DA, Curd JG. Activation of the classical pathway of complement by rheumatoid factors. Assessment by radioimmunoassay for C4. Arthritis Rheum 1982;25:161-67.

XXI. Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol 2015;194:3664-74.

XXII. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.

XXIII. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.

XXIV. Mohanan S, Cherrington BD, Horibata S, McElwee JL, Thompson PR, Coonrod SA: Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int. 2012;2012:895343. Epub 2012 Sep 16.

XXV. Schauer C, Janko C, Munoz LE, Zhao Y, Kienhöfer D, Frey B, et al: Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014 May;20(5):511-7.

XXVI. Reynisdottir G, Olsen H, Joshua V, et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis 2015.

XXVII. Lugli EB, Correia RE, Fischer R, Lundberg K, Bracke KR, Montgomery AB, et al: Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Res Ther. 2015 Jan 20;17:9.

XXVIII. Nielen MM, van Schaardenburg D, Reesink WH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-86.

XXIX. van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, et al: EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017 Mar;76(3):491-496.

XXX. Rombouts Y, Willemze A, van Beers JJ, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 2016;75:578-85.

XXXI. Rombouts Y, Ewing E, van de Stadt LA, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2015;74:234-41.